Galectin-3 is elevated in CSF and is associated with Aβ deposits and tau aggregates in brain tissue in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Galectin-3 (Gal-3) is a beta-galactosidase binding protein involved in microglial activation in the central nervous system (CNS). We previously demonstrated the crucial deleterious role of Gal-3 in microglial activation in Alzheimer’s disease (AD). Under AD conditions, Gal-3 is primarily expressed by microglial cells clustered around Aβ plaques in both human and mouse brain, and knocking out Gal-3 reduces AD pathology in AD-model mice. To further unravel the importance of Gal-3-associated inflammation in AD, we aimed to investigate the Gal-3 inflammatory response in the AD continuum. First, we measured Gal-3 levels in neocortical and hippocampal tissue from early-onset AD patients, including genetic and sporadic cases. We found that Gal-3 levels were significantly higher in both cortex and hippocampus in AD subjects. Immunohistochemistry revealed that Gal-3+ microglial cells were associated with amyloid plaques of a larger size and more irregular shape and with neurons containing tau-inclusions. We then analyzed the levels of Gal-3 in cerebrospinal fluid (CSF) from AD patients ( n = 119) compared to control individuals ( n = 36). CSF Gal-3 levels were elevated in AD patients compared to controls and more strongly correlated with tau (p-Tau181 and t-tau) and synaptic markers (GAP-43 and neurogranin) than with amyloid-β. Lastly, principal component analysis (PCA) of AD biomarkers revealed that CSF Gal-3 clustered and associated with other CSF neuroinflammatory markers, including sTREM-2, GFAP, and YKL-40. This neuroinflammatory component was more highly expressed in the CSF from amyloid-β positive (A+), CSF p-Tau181 positive (T+), and biomarker neurodegeneration positive/negative (N+/−) (A + T + N+/−) groups compared to the A + T−N− group. Overall, Gal-3 stands out as a key pathological biomarker of AD pathology that is measurable in CSF and, therefore, a potential target for disease-modifying therapies involving the neuroinflammatory response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Fig. 5 CSF Gal-3 levels are increased in AD patients and correlate with other CSF neuroinflammatory biomarkers. a CSF Gal-3 levels were measured by ELISA in control subjects and AD patients. Gal-3 levels were significantly elevated in AD patients compared to controls (*P = 0.030) after adjustment on age, sex and ApoE4 carriership. b CSF sTREM-2 levels were measured in our cohort. No difference was found between the AD and control groups in our analysis adjusted for age, sex and ApoE4 carriership (P = 0.217). c, d Analysis of ROC curves revealed moderate performance of CSF Gal-3 and sTREM-2 levels for differentiating AD patients from neurological controls (c Gal-3 AUROC = 0.80 [95% CI = 0.72–0.88], sTREM-2 AUROC = 0.78 [95% CI = 0.69–0.88]; d Gal-3 AUPRC = 0.92, sTREM-2 AUPRC = 0.91). For comparison, CSF markers p-tau and t-tau demonstrated high discriminating performance between AD and controls (c: p-tau AUROC = 0.95 [95% CI = 0.91–1.00], t-tau AUROC = 0.92 [95% CI = 0.86–0.98]; 5d: p-tau AUPRC = 1.00, t-tau AUPRC = 0.99). e, f, g The relationships between CSF Gal-3 and other CSF neuroinflammatory biomarkers—sTREM-2, GFAP and YKL-40—were studied using Spearman’s rank correlation in the whole cohort as well as in AD and neurological control (NC) subgroups](https://figures.cochat.ai/paper-figures/fd6f445758894d55a05f64ee203dc3c3/galectin-3-is-elevated-in-csf-and-is-associated-with-a-deposits-and-tau-figure-5.jpg)
![Fig. 6 CSF Gal-3 levels correlate with CSF tau and synaptic markers. a–o Scatter plots depicting the association between CSF Gal-3 levels with other CSF AD and synaptic markers in the whole cohort and in the sub-groups (neurological controls [NC] n = 36 and AD n = 119). a–c CSF Aβ ratio weakly correlated with CSF Gal-3 in the whole cohort and sub-groups. d–i CSF Gal-3 significantly correlated with CSF p-tau181 and t-tau in the whole cohort and some sub-groups. j–o CSF Gal-3 levels correlated with CSF synaptic markers neurogranin j–l and GAP-43 m–o in the whole cohort and in the AD patient sub-group. Associations were assessed using Spearman’s rank correlation. Solid line indicates regression line, and dotted lines border the 95% confidence interval](https://figures.cochat.ai/paper-figures/dea1229b8bbd4c60b9d757f72eba6983/galectin-3-is-elevated-in-csf-and-is-associated-with-a-deposits-and-tau-figure-6.jpg)
![Fig. 7 CSF Gal-3 clusters with a neuroinflammatory component in principal component analysis. a, b Principal component analysis (PCA) in the whole cohort revealed clustering of the CSF biomarkers in two principal components (a loading values of each CSF biomarker, eigenvalues, and variance explained for each component identified; b: scree-plot in Varimax rotation). Component 1 is associated with CSF core AD biomarkers (Aß ratio, p-Tau181, and t-tau) and CSF synaptic markers (neurogranin, GAP-43). Component 2 included the CSF neuroinflammation markers (Gal-3, sTREM-2, GFAP, and YKL-40). Component 1 and Component 2 accounted for 57% and 14% of the variance. c–e Identified components were compared between groups using one-way ANCOVA-adjusted on age and sex followed by post hoc Least square test, adjusted with Bonferroni for multiple comparisons. c Core AD Component 1 was significantly higher in AD patients than in all other groups (****P < 0.0001 versus all other groups). d Neuroinflammation Component 2 did not differ between the groups. e Focusing on the patients on the AD continuum, neuroinflammatory Component 2 was significantly higher in patients with a [A + T + N +] CSF profile compared to patients with an [A + T−N−] profile (P = 0.002)](https://figures.cochat.ai/paper-figures/317c064a02154400aeb3b50772fc26a2/galectin-3-is-elevated-in-csf-and-is-associated-with-a-deposits-and-tau-figure-7.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In both AD patients and Aβ amyloidosis model mice, Gal-3 is significantly elevated in microglia clustered around Aβ plaques, where it induces neuroinflammation and neurodegeneration17,18.”
From Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer’s disease models (2026) · cites this paper as [18]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537 · cited 2×
“AD diagnosis was made according to the NIAAAA’s most recent diagnostic research criteria [25].”
Self-citationA Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493 · cited 3×
“Brain expression of TREM-2 has also been linked to disease-associated microglial phenotype and plaque growth dynamics [29, 32, 54, 61].”
Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner
Schafer, D. P., Lehrman, E. K., Kautzman, A. G., Koyama, R., Mardinly, A. R., Yamasaki, R., Ransohoff, R. M., Greenberg, M. E., Barres, B. A., & Stevens, B. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.026 · Cited by 4,089 · cited 1×
“In AD, microglia constitute a cellular mediator of synapse loss through phagocytosis or release of synaptotoxic factors [9, 22, 36, 45].”
Complement and microglia mediate early synapse loss in Alzheimer mouse models
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., et al. (2016) · Science · doi:10.1126/science.aad8373 · Cited by 3,343 · cited 2×
“Synaptic dysfunction is an early feature in AD, and recent studies suggest that microglia-mediated synapse removal could be a contributing factor [22].”
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179 · cited 1×
“This quadratic relation might reflect the evolution of microglial activation over different stages of the pathology [33, 37].”
Krasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.008 · Cited by 2,979 · cited 5×
“[30], depends on TREM-2-ApoE signaling, shares similarities with the DAM phenotype, and involves key genes such as Gal-3, Clec7a, Itgax and Spp1.”
InfluentialA/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., Hampel, H., Jagust, W. J., Johnson, K. A., Knopman, D. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002923 · Cited by 1,864 · cited 1×
“CSF profile was classified according to the ATN classification: A+/− indicating biomarker evidence of Aβ deposition; T ± indicating biomarker evidence of pathologic tau; and N+/− indicating biomarker evidence of neurodegeneration [26].”
Self-citationTREM2 Maintains Microglial Metabolic Fitness in Alzheimer’s Disease
Ulland, T. K., Song, W. M., Huang, S. C.-C., Ulrich, J. D., Sergushichev, A., Beatty, W. L., Loboda, A. A., Zhou, Y., Cairns, N. J., Kambal, A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.023 · Cited by 1,263 · cited 1×
“Brain expression of TREM-2 has also been linked to disease-associated microglial phenotype and plaque growth dynamics [29, 32, 54, 61].”
Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group
Dubois, B., Villain, N., Frisoni, G. B., Rabinovici, G. D., Sabbagh, M., Cappa, S., Bejanin, A., Bombois, S., Epelbaum, S., Teichmann, M., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00066-1 · Cited by 1,051 · cited 2×
“Traditionally, Aβ, p-Tau and tau are the main diagnostic biomarkers for AD used in clinical practice [16].”
Self-citationMicroglial signatures and their role in health and disease
Butovsky, O., & Weiner, H. L. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0057-5 · Cited by 1,046 · cited 1×
“They play diverse roles, including brain parenchyma surveillance, phagocytosis, synaptic remodeling, and inflammatory response [11].”
Cited by
Targeting galectin-3 in inflammatory and fibrotic diseases
Bouffette, S., Botez, I., & De Ceuninck, F. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.06.001 · Cited by 165
Microglia dynamics in aging-related neurobehavioral and neuroinflammatory diseases
Javanmehr, N., Saleki, K., Alijanizadeh, P., & Rezaei, N. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02637-1 · Cited by 119
Noh, M., Kwon, H. S., Kwon, M., Nahm, M., Jin, H. K., Bae, J., & Kim, S. H. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00867-4 · Cited by 97
Melchiorri, D., Merlo, S., Micallef, B., Borg, J.-J., & Dráfi, F. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1196413 · Cited by 70
“, 2019), and galectin-3 levels in blood or CSF were shown to be elevated in AD patients (Wang X. et al., 2015; Yazar et al., 2021; Boza-Serrano et al., 2022).”
BackgroundBiomarkers in Alzheimer’s disease
Rajendran, K., & Krishnan, U. M. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.119857 · Cited by 58
Xue, S., Lozinski, B. M., Ghorbani, S., Ta, K., D’Mello, C., Yong, V. W., & Dong, Y. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.2312-22.2023 · Cited by 49
Galectin-3 shapes toxic alpha-synuclein strains in Parkinson’s disease
García‐Revilla, J., Boza‐Serrano, A., Jin, Y., Vadukul, D. M., Soldán-Hidalgo, J., Camprubí-Ferrer, L., García-Cruzado, M., Martinsson, I., Klementieva, O. L., Ruiz, R., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02585-x · Cited by 42
“More recently, we have established GAL3 as a critical pathological CSF biomarker of AD, strongly associated with other key AD CSF biomarkers [8].”
BackgroundSelf-citationYKL-40 as a biomarker in various inflammatory diseases: A review
Hrabar, D., Bakula, D., Vrkljan, N., Ratkajec, V., Glavčić, G., Miler, M., Pelajić, S., Rogić, D., Blažević, N., & Pavić, T. (2023) · Biochemia Medica · doi:10.11613/bm.2024.010502 · Cited by 63
Kram, M. T. (2023) · World Journal of Hepatology · doi:10.4254/wjh.v15.i2.201 · Cited by 42
Emerging role of galectin 3 in neuroinflammation and neurodegeneration
Lozinski, B. M., Ta, K., & Dong, Y. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.391181 · Cited by 41
Lysosome quality control in health and neurodegenerative diseases
Ferrari, V., Tedesco, B., Cozzi, M., Chierichetti, M., Casarotto, E., Pramaggiore, P., Cornaggia, L., Mohamed, A. A., Patelli, G., Piccolella, M., et al. (2024) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00633-2 · Cited by 47
“This evidence includes galectin-3 accumulation in Aβ plaques in microglia, mediating the maladaptive activation of the inflammatory response [210]; dysregulation in endosome– and lysosome–ER contact sites due to amyloid precursor protein (APP) [211]; increased alkalinization in neuronal lysosomes…”
BackgroundPectin: Health-promoting properties as a natural galectin-3 inhibitor
An, L., Chang, G., Zhang, L., Wang, P., Gao, W., & Li, X. (2024) · Glycoconjugate Journal · doi:10.1007/s10719-024-10152-z · Cited by 31
“…studies have shown that levels of Gal-3 in hereditary AD are sig - nificantly upregulated in both the cortex and hippocampus, that elevated Gal-3 levels are associated with neuroinflam - mation, and that levels of Gal-3 in cerebrospinal fluid are associated with cognitive decline in AD [ 125].”
Nuñez‐Diaz, C., Andersson, E., Schultz, N., Pocevičiūtė, D., Hansson, O., Bank, T. N. B., Nilsson, K. P. R., & Wennström, M. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01375-7 · Cited by 25
Self-citationGuo, L., Reed, K. M., Carter, A. M., Cheng, Y., Roodsari, S. K., Pineda, D. M., Wellman, L. L., Sanford, L. D., & Guo, M. (2022) · Cells · doi:10.3390/cells12010160 · Cited by 26
“Gal3 has been suggested to be a novel neuroinflammation marker [63] and increased Gal3 levels have been identified in multiple neurodegenerative diseases including Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, and amyotrophic lateral sclerosis [47,48].”
BackgroundGalectin‐3 is upregulated in frontotemporal dementia patients with subtype specificity
Borrego‐Écija, S., Pérez‐Millan, A., Antonell, A., Fort‐Aznar, L., Tilki, E. K., León‐Halcón, A., Lladó, A., Molina‐Porcel, L., Balasa, M., Juncà‐Parella, J., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13536 · Cited by 22
“24 Therefore, Gal-3 ′ s unique expression, pivotal role in microglial activation, and relevance in FTD progression mark it as a key molecule for future exploration, differentiating it from other galectins in understanding neuroinflammation in neurodegenerative disorders.”
BackgroundResultInfluentialSelf-citationMohammadi, H., Ariaei, A., Ghobadi, Z., Gorgich, E. A. C., & Rustamzadeh, A. (2024) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2024.02.007 · Cited by 19
Krix, S., Wilczynski, E., Falgàs, N., Sánchez‐Valle, R., Yoles, E., Nevo, U., Baruch, K., & Fröhlich, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1343900 · Cited by 23
Self-citationPitts, K. M., Neeson, C. E., Hall, N. E., Lin, J. B., Falah, H. K., Wang, S. L., Lo, K., Song, C., Margeta, M. A., & Valle, D. S.-D. (2022) · Translational Vision Science & Technology · doi:10.1167/tvst.11.11.1 · Cited by 16
Biofluid biomarkers for Alzheimer’s disease: past, present, and future
An, C., Cai, H., Ren, Z., Fu, X., Quan, S., & Jia, L. (2024) · Medical Review · doi:10.1515/mr-2023-0071 · Cited by 14
“CSF sTREM2 is increased in individuals with AD [119].”
Guo, X., Zhang, G., Peng, Q., Liu, H., Ye, K., Xiao, T., Liu, C., Zhang, X., Li, S., Wang, H., et al. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.106158 · Cited by 14
AI-driven discovery of brain-penetrant Galectin-3 inhibitors for Alzheimer's disease therapy
Liu, X., Xu, J., Zheng, S., Yang, Y., Xie, Y., Liu, J., Zhong, J., Zhang, H., Chen, J., Dai, C., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107834 · Cited by 16
Hypercholesterolemia drives microglial dysfunction and weakens response to amyloid plaques
Kaye, S. D., Gold, A., Lin, D., Chen, M., Zhu, J., & Gao, J. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115272 · Cited by 11
Microglia‐derived Galectin‐9 drives amyloid‐β pathology in Alzheimer's disease
Zhang, G., Peng, Q., Guo, X., Pan, L., Xiong, M., Zhang, X., Dai, L., Zhang, Z., Xiao, T., He, J., et al. (2024) · Aging Cell · doi:10.1111/acel.14396 · Cited by 13
“Conversely, Gal-3 acts as an endogenous TREM2 ligand and detrimentally regulates the inflammatory response and promotes cognitive dysfunction (Boza-Serrano et al., 2019, 2022; Tao et al., 2020).”
Inflammation‐Derived and Clinical Indicator‐Based Predictive Model for Ischemic Stroke Recovery
Luo, J. M., Cai, Y., Xiao, P., Cao, C., Huang, M., Zhang, X., Jie, G., Huo, Y., Tang, Q., Zhao, L., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.035609 · Cited by 9
“32 33-35 Research on molecular mechanisms has provided increasing evidence supporting that LGALS3 modulates the phenotype of microglia activation involved in neuroinflammation under neurodegeneration conditions.”
Immunological Fluid Biomarkers in Frontotemporal Dementia: A Systematic Review
Erichsen, P. A., Henriksen, E. E., Nielsen, J. E., Ejlerskov, P., Simonsen, A. H., & Toft, A. D. (2025) · Biomolecules · doi:10.3390/biom15040473 · Cited by 9
“YKL-40 is positively correlated with neuroinflammatory markers, including CSF Galectin-3, GFAP, and triggering receptor expressed on myeloid cells 2 (TREM2) [135].”
Impairment of lysosomal quality control in Huntington disease
Rusmini, P., Mina, F., Valenza, M., Vitali, M., Ferrari, V., Tedesco, B., Casarotto, E., Cozzi, M., Chierichetti, M., Mohamed, A., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08103-z · Cited by 10
“Interestingly, LGALS3 was found increased in the cerebrospinal fl uid of Alzheimer disease patients and involved in the unconventional secretion of these spreading aggregates in Alzheimer and Parkinson disease [71 – 74].”
Modulation of the cytoskeleton for cancer therapy
Matov, A. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1681065 · Cited by 8
Kim, B., Tate, M. D., Karahan, H., Wijeratne, H. R. S., Sharify, A. D., Wang, S. S., Kim, J. R., Al-Amin, M. M., Hartigan, K., Chung, S., et al. (2026) · Neuron · doi:10.1016/j.neuron.2026.03.011 · Cited by 6
More than microglia: myeloid cells and biomarkers in neurodegeneration
Kodosaki, E., Bell, R., Sogorb‐Esteve, A., Wiltshire, K., Zetterberg, H., & Heslegrave, A. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1499458 · Cited by 6
Yuan, J., Dong, X., Gao, Y. L., & Nao, J. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00744 · Cited by 8
Demir, M. T., Elbe, H., Çetinavcı, D., & Saruhan, E. (2025) · Inflammation · doi:10.1007/s10753-025-02301-9 · Cited by 10
Implications of Mucin-Type O-Glycosylation in Alzheimer’s Disease
Navarro, N. V., Mundim, G. D. N., & Čudić, M. (2025) · Molecules · doi:10.3390/molecules30091895 · Cited by 5
High blood galectin-3 level associated with risk of frailty in aging
Ji, X., Jiang, Z., Qiu, Y., Yu, J., Zhang, Y., Wang, J., Ye, B., Huang, Y., Gu, W., Huang, Y., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1189192 · Cited by 6
“As to the neuroinflammation and neurodegeneration in the brain, previous studies mentioned that Gal-3 stands out as a key pathological biomarker of AD pathology (43, 44), which was consistent with our KEGG analysis results (Figure 3D).”
ResultGarcia, M. G., Paulus, A., Vázquez‐Reyes, S., Klementieva, O. L., Gouras, G. K., Bachiller, S., & Deierborg, T. (2023) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2023.100663 · Cited by 8
Self-citationEtxeberría, A., Lee, S.-H., Kuhn, J., Callow, M. G., Novikova, G., Fortin, J., Choy, M. K., Xie, L., Imperio, J., Vito, S., et al. (2026) · Neuron · doi:10.1016/j.neuron.2026.02.023 · Cited by 5
Shin, H. J., Kim, K. E., Jeong, E. A., An, H. S., Lee, S. J., Lee, J., & Roh, G. S. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.05.026 · Cited by 7
Quantitative Cell Division and Migration in MedicinePreprint
Matov, A. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5130515 · Cited by 10
Pachter, D., Meir, A. Y., Kaplan, A., Tsaban, G., Zelicha, H., Rinott, E., Levakov, G., Finkelstein, O., Shelef, I., Salti, M., et al. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.08.021 · Cited by 3
“Higher Gal-3 levels are correlated with tau and p-Tau181 levels, two indicators of pathology progression in AD [46,47].”
Siew, J. J., & Chern, Y. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107410 · Cited by 2
Zhen, W., Wang, Y., Zhen, H., Zhang, W., Shao, W., Sun, Y., Qiao, Y., Jia, S., Zhou, Z., Wang, Y., et al. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1513930 · Cited by 1
Akash, A., Ahamed, M., Porel, P., & Aran, K. R. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149949 · Cited by 3
Positive correlation between plasma and cerebrospinal fluid galectin-3 in suicide attempters
Bonţidean, A., Lindqvist, D., Grudet, C., Brundin, L., Deierborg, T., & Ventorp, F. (2025) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2025.2597331 · Cited by 1
Self-citationGalectin-3 shapes microglial phenotype through endogenous and exogenous mechanisms
Camprubí-Ferrer, L., Yang, Y., Fernández‐Calle, R., Boza‐Serrano, A., García‐Revilla, J., Frontiñán-Rubio, J., & Deierborg, T. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1729776 · Cited by 3
Self-citationBerbamine hydrochloride as a brain-penetrant galectin-3 inhibitor in a model of Huntington’s disease
Siew, J. J., Lee, C., Chen, H.-M., Lin, H., Liu, Y.-L., Lee, Y.-H., Wu, Y. X., Chen, H.-L., Liu, F., Lin, C.-H., et al. (2026) · Brain · doi:10.1093/brain/awag069 · Cited by 4
“36,44,45 Gal3 was upregulated in microglia in human and mouse models of tauo-pathy, such as AD, where it promoted the accumulation of pathogenic tau and enhanced tau fibrillation.”
Camprubí-Ferrer, L., Kolbay, Ö. K., Quattromani, M. J., Wieloch, T. W., Ruscher, K., & Deierborg, T. (2026) · Neuroprotection/Neuroprotection (Chichester, England. Print) · doi:10.1002/nep3.70028 · Cited by 1
Self-citationImmune receptor LAG3 regulates microglia function during Alzheimer's disease
Perl, A. T., Wu, J., Dong, J. D., Brooks, A. M., Yoblinski, A. R., Vierling, T. T., Li, J., Ruby, D. R., Radzicki, D., Dudek, S. M., et al. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107447 · Cited by 2
Ai-Driven Discovery of Brain-Penetrant Galectin-3 Inhibitors for Alzheimer's Disease TherapyPreprint
Ye, Z., Liu, X., Xu, J., Zheng, S., Zhong, J., Yang, Y., Xie, Y., Zhang, H., Chen, J., Dai, C., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5144196 · Cited by 1
Editorial: Present and future of biological fluid biomarkers in dementia
Frontiñán-Rubio, J., Rabanal‐Ruiz, Y., Peinado, J. R., & Deierborg, T. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1331799 · Cited by 1
Self-citationAn Inflammation-Derived and Clinical-Based Model for Ischemic Stroke RecoveryPreprint
Luo, J., Cai, Y., Xiao, P., Cao, C., Huang, M., Zhang, X., Jie, G., Huo, Y., Tang, Q., Zhao, L., et al. (2024) · medRxiv · doi:10.1101/2024.02.18.24303013
Metadynamics and Free-Energy Landscape Approaches for Structural Characterization of Galectin-3Preprint
Ganguly, R., Uversky, V. N., Ingty, P., Ngoruh, A., Yadav, S. K., Roy, R., & Bhattacharjee, A. (2024) · Research Square · doi:10.21203/rs.3.rs-4604896/v1
Pachter, D., Meir, A. Y., Kaplan, A., Tsaban, G., Zelicha, H., Rinott, E., Levakov, G., Finkelstein, O., Shelef, I., Salti, M., et al. (2024) · medRxiv · doi:10.1101/2024.11.19.24317485
Galectin-3 links microglial neuroinflammation to Aβ aggregation and lysosomal processing
Camprubí-Ferrer, L., Soldán-Hidalgo, J., Axell, E., Dell’Eva, M., García-Cruzado, M., García‐Revilla, J., Yang, Y., Fernández‐Calle, R., Larlham, L., Chouhan, B., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1101/2025.03.17.643790 · Cited by 1
“We recently identified Gal3 as a potential cerebrospinal fluid biomarker for AD (18) and tau-dependent frontotemporal dementia (23).”
InfluentialSelf-citationFluid and Imaging Markers of Glial Reactivity
Suárez‐Calvet, M. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_6 · Cited by 1
Martínez-García, J., Fernández, B., Artime, E., Álvarez, L., González‐Iglesias, H., Clases, D., & Pereiro, R. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c03630
Mani, R. R., Panneerselvam, J., Chinnappan, S., & Ranganathan, V. (2025) · Current Drug Therapy · doi:10.2174/0115748855404595250908114801
Nuñez‐Diaz, C., Andersson, E., Schultz, N., Pocevičiūtė, D., Hansson, O., Nilsson, K. P. R., & Wennström, M. (2024) · Figshare · doi:10.6084/m9.figshare.24934682
Self-citationNuñez‐Diaz, C., Andersson, E., Schultz, N., Pocevičiūtė, D., Hansson, O., Nilsson, K. P. R., & Wennström, M. (2024) · Figshare · doi:10.6084/m9.figshare.24934406
Self-citationPlasma Proteomics and Sensitive Imaging Biomarkers of Vascular Brain InjuryPreprint
Yang, Q., Guðmundsdóttir, V., McGrath, E. R., Sargurupremraj, M., Zhu, Y., Maillard, P., CHEN, Z.-Z., Satizábal, C. L., Tahir, U. A., Beiser, A., et al. (2026) · medRxiv · doi:10.64898/2026.01.19.26344369
Research progress and translational application of GAP-43
Liu, Y.-E., & Zhang, X. (2025) · Integrate Medicine · doi:10.61958/imhq3849
The Peripheral Immune-Sleep- Cognition Axis Across Diagnostic Stages of Alzheimer’s DiseasePreprint
Krix, S., Falgàs, N., Hücker, S. M., Pérez‐Millan, A., Antonell, A., Ruiz‐García, R., Lorca‐Arce, D., Stadler, C., Proske, J., Braiman, S., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9574288/v1
Self-citationChronic pain in Alzheimer disease and the role of neuroimmune interactions
Malcangio, M., & Sideris-Lampretsas, G. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100149
The Environmental Contribution to Health and Disease: Analytical Tools for Monitoring and Diagnosis
Aranda‐Merino, N., Heras, C. G. D. L., Ramos‐Payán, M., Fernández‐Torres, R., Bello‐López, M. Á., & Gómez‐Ariza, J. L. (2026) · Environments · doi:10.3390/environments13080416 · Cited by 1
Zhou, Y., Diao, Y., Yan, Z., Shui, X., Huang, Z., Sun, Y., Wang, S. W., Xia, Y., Lee, T. H., & Wang, L. (2026) · Biomolecules · doi:10.3390/biom16081075
“Considering that Gal3 [64–66] and PU.1 [67,68] have been demonstrated to play critical roles in A β pathologies, we next investigated the regulatory effects of miR-143-3p on Gal3 and PU.1 expression in the hippocampus and cortex of the brain.”
Yang, T., Yang, Y., Cheng, J., Fan, K., Ma, Y., Zou, D., & Yu, S. (2026) · Neurosurgical Subspecialties · doi:10.14218/nsss.2026.00014
Protective role of Galectin‐3 in prion disease through regulation of microglial PrP Sc uptake
Makarava, N., Safadi, T., Pandit, N. P., Mychko, O., Bocharova, O. V., Shevelkin, A. V., Molesworth, K., Lipinski, M. M., & Baskakov, I. V. (2026) · Brain Pathology · doi:10.1111/bpa.70161 · Cited by 1
“In the 5XFAD mouse model of AD, Gal3 expression was markedly elevated in plaque-associated microglia, whereas Gal3 deletion reduced amyloid-β burden and improved cognitive performance [31].”
Metadata
- Authors
- Boza-Serrano, A., Vrillon, A., Minta, K., Paulus, A., Camprubí-Ferrer, L., Garcia, M., Andreasson, U., Antonell, A., Wennström, M., Gouras, G., Dumurgier, J., Cognat, E., Molina-Porcel, L., Balasa, M., Vitorica, J., Sánchez-Valle, R., Paquet, C., Venero, J. L., Blennow, K., & Deierborg, T.
- Affiliations
- Inserm (FR)
- University of Gothenburg (SE)
- Lund University (SE)
- Hospital Clínic de Barcelona (ES)
- Instituto de Biomedicina de Sevilla (ES)
- Sahlgrenska University Hospital (SE)
- Corresponding author
- Vrillon, Agathe
- ORCID
- Venue
- Acta Neuropathologica
- Published
- 2022-07-27
- Volume
- 144
- Issue
- 5
- Pages
- 843-859
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC9547798
- OpenAlex
- W4288177782
- Cited by
- 66
- References
- 63
- Citations by year
- 2026: 15 · 2025: 20 · 2024: 16 · 2023: 12 · 2022: 3
- FWCI
- 7.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Acta Neuropathologica (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- Deposito de Investigacion Universidad de Sevilla (University of Seville) (submittedVersion, cc-by)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, cc-by)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion, cc-by)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Vetenskapsrådet (2019-0633)
- Ministerio de Ciencia, Innovación y Universidades (RTI2018-098645-B-100, PID2021-124096OB-100)
- Instituto de Salud Carlos III (20/00448, Union PI18/01556, PI21/00914)
- Consejería de Economía, Innovación, Ciencia y Empleo, Junta de Andalucía (P18-RT-1372, US-1262734)
- Kungliga Fysiografiska Sällskapet i Lund (20191114ABS, 20211129ABS)
- Greta och Johan Kocks stiftelser (20201201ABS)
- Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía (US-1264806)
- Lund University
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- galectin-3, Alzheimer's disease, cerebrospinal fluid biomarkers, amyloid plaques, tau inclusions, neuroinflammation, microglial activation, p-tau181, neurogranin, GAP-43, glial fibrillary acidic protein, YKL-40, hippocampus, neocortex, early-onset Alzheimer's disease, disease-modifying therapy
- MeSH terms
- Chitinase-3-Like Protein 1, Alzheimer Disease, Animals, beta-Galactosidase, Brain, Humans, Biomarkers, Amyloid beta-Peptides, tau Proteins, GAP-43 Protein, Galectin 3, Mice, Neurogranin, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.